热熔挤出法制备阿瑞匹坦固体分散体

发布时间：2018-03-23 23:29

  本文选题：热熔　切入点：定仪　出处：《中国医药工业杂志》2016年08期

【摘要】：正[Drug Dev Ind Pharm,2016,42(10):1609]采用基团贡献法评价BCSⅡ类药物阿瑞匹坦(APR)和载体Soluplus(SOL)的溶解度参数。通过加热-冷却-加热的差示扫描量热(DSC)分析评估APR的玻璃化形成能力(glass forming ability,GFA)和玻璃化稳定性(glass stability,GS)。根据物理混合物熔点的下降情况确定热熔挤出(HME)过程的优化温度。采用动态湿气吸附测定仪收集25℃时的吸附等温线。
[Abstract]:The solubility parameters of Drug Dev Ind Pharmatorum 422 10: 1609 were evaluated by group contribution method. The glass forming ability of APR was evaluated by means of heat-cooling-heating differential scanning calorimetry (DSCA). The glass-forming ability of APR was evaluated by glass forming capability. The optimum temperature of the hot melt extrusion (HME) process was determined according to the decrease of melting point of the physical mixture. The adsorption isotherms at 25 鈩，

本文编号：1655711